5 Results for "

symmetric dimethyl arginine

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "symmetric dimethyl arginine" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-101410
CAS No.: 30344-00-4
Purity:  ≥98.0%
Synonyms: symmetric dimethylarginine; NG,NG'-dimethyl-L-arginine
SDMA (Symmetric dimethylarginine) is an endogenous inhibitor of nitric oxide (NO) synthase activity. SDMA, a novel kidney biomarker, permits earlier diagnosis of kidney disease than traditional creatinine testing.
loading...
    loading...
Cat. No.: HY-101410S
CAS No.: 1331888-08-4
Purity:  98.07%
Synonyms: symmetric dimethylarginine-d6; NG,NG'-dimethyl-L-arginine-d6
SDMA-d6 is the deuterium labeled SDMA. SDMA (Symmetric dimethylarginine) is an endogenous inhibitor of nitric oxide (NO) synthase activity .
loading...
    loading...
Cat. No.: HY-101410R
CAS No.: 30344-00-4
Synonyms: symmetric dimethylarginine (Standard); NG,NG'-dimethyl-L-arginine (Standard)
SDMA (Standard) is the analytical standard of SDMA. This product is intended for research and analytical applications. SDMA (Symmetric dimethylarginine) is an endogenous inhibitor of nitric oxide (NO) synthase activity. SDMA, a novel kidney biomarker, permits earlier diagnosis of kidney disease than traditional creatinine testing.
loading...
    loading...
Cat. No.: HY-101410A
CAS No.: 1266235-58-8
Synonyms: symmetric dimethylarginine (p-hydroxyazobenzene-p′-sulfonate); NG,NG'-dimethyl-L-arginine (p-hydroxyazobenzene-p′-sulfonate)
SDMA p-hydroxyazobenzene-p′-sulfonate is the p-hydroxyazobenzene-p′-sulfonate salt form of SDMA (HY-101410). SDMA p-hydroxyazobenzene-p′-sulfonate is an endogenous inhibitor of nitric oxide synthase (NO synthase) activity. SDMA p-hydroxyazobenzene-p′-sulfonate is an activator for NF-κB, and promotes the expression of IL-6 and TNF-α. SDMA p-hydroxyazobenzene-p′-sulfonate is stable in serum and plasma, and can be used as a kidney biomarker of hepatic and renal dysfunction .
loading...
    loading...
Cat. No.: HY-183568
Research Areas:  

Cancer

MAT2A-IN-26 is an orally active MAT2A inhibitor with a human IC50 of 17.53 nM. MAT2A-IN-26 inhibits the enzymatic activity of MAT2A, thereby reducing the levels of S-adenosylmethionine (SAM) and symmetric dimethylarginine (sDMA). MAT2A-IN-26 inhibits the proliferation of MTAP-deficient cancer cells and induces anti-tumor efficacy in xenograft models. MAT2A-IN-26 can be used in non-small cell lung cancer research .
loading...
    loading...